4 hours Rhythm Pharmaceuticals (NASDAQ:RYTM) Given “Buy” Rating at HC Wainwright MarketBeat
HC Wainwright reaffirmed a “buy” rating and set a $64.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday.
Nasdaq 100 · Pharmaceuticals · Science